Background: Phosphorylcholine (PC) coated stent had a similar clinical event rate and restenosis rate compared with bare metal stent in previous studies. Dexamethasone(DEX) has anti-inflammatory and immunosuppressive effects, in part through the inhibition of cytokine release. A recent pilot study demonstrated DEX coated Bio DD stent was a safe drug eluting stent and effectively reduced instent restenosis and MACE rates. Methods: A prospective trial including 92 patients (98stents) randomized by period to either DEX eluting Bio DD PC coated stent (67patients, 71 stents) or Bio DD PC coated stent without DEX (25 patients, 27stents). The exclusion criteria were primary angioplasty in AMI patients, CTO lesion, left main lesion, bifurcation intervention, vein graft lesion, severe calcified lesion, thrombus containing lesion, restenosis lesion. The primary end-point of the study was 12-months MACE rate. The secondary end-point was 6-months angiographic restenosis rate. Results: Demographics are as follows : Mean age is 60.6 years ; 58% are male ; 38% are dialetic, and 33% and 57% hypercholesterolemic and hypertensive respectively. Baseline demographics and lesion characteristics were not different in both groups. Angiographic follow-up rates were 80.3% in DEX group and 77.8% in non DEX group. The 12-months MACE rate and 6-months angiographic findings are shown in table. Conclusions: DEX eluting Bio DD PC coated stent can significantly reduce in-stent restenosis and prevent MACE compared with Bio DD PC Coated Stent without DEX.